Abstract: The present invention is related to a product comprising a pentacyclic triterpene of formula (I) and a hydroxytyrosol or derivatives thereof of formula (II), pharmaceutical compositions thereof and their uses as antioxidants, anti-inflammatories and neuron protectors.

Abstract: A microfluidic valve includes: a first structural layer and a second structural layer; a microfluidic circuit having a first microfluidic conduit and a second microfluidic conduit, which are defined in a superficial portion of the first structural layer, are adjacent, and are separated by a wall; a membrane set between the first structural layer and the second structural layer and delimiting the microfluidic circuit on one side; and a recess containing a gaseous fluid in the second structural layer. The membrane is movable in response to an actuation stimulus between a closed position, in which the first and second microfluidic conduits are fluidly decoupled, and an open position, in which the membrane is at least in part retracted into the recess and the first and second microfluidic conduits are fluidly coupled by means of a fluidic passage defined between the wall and the membrane.

Abstract: The present invention is related to a product comprising a pentacyclic triterpene and hydroxytyrosol or derivatives thereof, uses, and pharmaceutical composition thereof.

Abstract: A microfluidic valve includes: a first structural layer and a second structural layer; a microfluidic circuit having a first microfluidic conduit and a second microfluidic conduit, which are defined in a superficial portion of the first structural layer, are adjacent, and are separated by a wall; a membrane set between the first structural layer and the second structural layer and delimiting the microfluidic circuit on one side; and a recess containing a gaseous fluid in the second structural layer. The membrane is movable in response to an actuation stimulus between a closed position, in which the first and second microfluidic conduits are fluidly decoupled, and an open position, in which the membrane is at least in part retracted into the recess and the first and second microfluidic conduits are fluidly coupled by means of a fluidic passage defined between the wall and the membrane.

Abstract: The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis.

Abstract: The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburg's acute M S, Balós's concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO).

Abstract: The invention relates to immunogenic peptide sequences and antibodies against said immunogenic agents for treating, preventing and/or diagnosing in human and non-human mammals a disease which is characterized by amyloid deposition, including involutive depression, confusional syndrome, dysthymia and cognitive Dysfunction Syndrome (CDS) in non-human mammals and different amyloidosis, including Alzheimer's disease in humans. Moreover, the invention provides diagnostic methods for the above diseases using the antibodies of the invention.

Abstract: KATP channel openers (KCOs) are useful for the prophylactic and/or therapeutic treatment of CNS chronic inflammation associated with a disease or state in a mammal, including a human. The administration of KCOs, including the groups of benzopirans, cyanoguanidines, thioformamides, benzothiadiazines, pyridyl nitrates, pyrimidine sulfates, cyclobutenediones, DHP-related compounds, tertiary carbinols, 6-sulfonil-chromenes, 1,2,3-triazoles, pyridothiadiazines, benzothiazines, halogenquinazolins and phenylbenzimidazoles, and in particular, the compound diazoxide, result in a reduction of reactive microglial response in various CNS pathologies such as axonal injury, brain tumors, traumatic damage, neurodegeneration, spinal cord injury, infectious and autoimmune diseases. KCOs, isotopically modified, are also useful for the preparation of diagnostic agents for detection and follow-up of CNS chronic inflammation.

Abstract: KATP channel closers (KCCs) are useful for the prophylactic and/or therapeutic treatment of a CNS acute damage in a mammal, including a human, because their administration, particularly in the case of glibenclamide, potientates the neuroprotector microglial effect. Therefore, they may be useful in treating the acute phase of CNS diseases such as stroke, seizure, axonal injury, traumatic damage, neurodegeneration, spinal cord injury, infectious and autoimmune CNS diseases. KCCs, isotopically modified, are also useful for the preparation of diagnostic agents for detection and follow-up of CNS acute damage.